Trethera News

Gloved hand of a scientist in a lab writing on a digital stilus with a digital pen.Blue DNA illustrationPhoto of a series of test tubes.Scientific microscope with visual representation of DNA helix

Trethera Receives $2M NIH Grant for Preclinical Development in the Pediatric Neurologic Disease Acute Disseminated Encephalomyelitis

July 16, 2024

Trethera secured a $2M NIH SBIR grant for preclinical development of TRE‑515 in treating pediatric ADEM. As the only drug with FDA Orphan Drug status in ADEM, TRE‑515 may enable trial design and exclusivity, supported by grant-funded rigor and regulatory advantages.

Read More

National Institute of Health to Fund Preclinical Development of Trethera Lead Drug, TRE-515, for Treatment of Crohn’s Disease

September 25, 2023

Trethera was awarded a $400K NIH STTR grant from NIDDK to translate proof-of-principle findings of oral TRE‑515 in treating Crohn’s disease—targeting autoreactive CD4 T cells via dCK inhibition for durable remission.

Read More

Globally Recognized Expert in Rare Neurologic Diseases, Dr. Michael Levy, Joins Trethera Scientific Advisory Board

September 5, 2023

Dr. Michael Levy, a distinguished expert in rare neurologic disorders, has joined Trethera’s Scientific Advisory Board to advise on TRE‑515’s development strategy and translational science across demyelinating and autoimmune neurological diseases.

Read More

Trethera Announces Invited Speaker Presentations at the Purine and Pyrimidine Society Symposium and General Assembly

June 28, 2023

At the 20th Annual Purine & Pyrimidine Society Symposium, Trethera will present two TRE‑515 research talks: one on its dCK‑inhibiting clinical trial mechanism, and another on its efficacy in MS mouse models.

Read More

Trethera Receives Grant from National Institute of Allergy and Infectious Diseases for the Advancement of TRE-515 in Lupus

June 27, 2023

Trethera was awarded a $0.6M Small Business STTR grant from NIAID to advance TRE‑515’s IND‑enabling development for systemic lupus erythematosus. This supports preclinical and biomarker studies to lay the foundation for SLE clinical trials.

Read More